Stereotactic Transplantation of hAESCs for Parkinson's Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Parkinson's Disease
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: The study plans to recruit 3 patients who meet the criteria. hAESCs of 50 million transplant to Parkinson's disease participants.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 30 years and 70 years
- Gender
- Both males and females
Description
The study plans to recruit 3 Parkinson's disease participants. Using stereotactic technology, hAESCs are accurately transplanted into the lateral ventricle. Therapeutic effect and safety of hAESCs on PD will be evaluated. hAESCs are derived from placental amnion donated after cesarean section in hea...
The study plans to recruit 3 Parkinson's disease participants. Using stereotactic technology, hAESCs are accurately transplanted into the lateral ventricle. Therapeutic effect and safety of hAESCs on PD will be evaluated. hAESCs are derived from placental amnion donated after cesarean section in healthy women. hAESCs is developed from the epiblast as early as 8 days after fertilization, recent reports indicate that hAESCs have some neural stem cell characteristics, can differentiate into dopaminergic neurons and secrete dopamine and various neurotrophic factors, which could be seen as one of the best potential stem cell source for treating Parkinson's disease.
Tracking Information
- NCT #
- NCT04414813
- Collaborators
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- Investigators
- Principal Investigator: WU Jingwen, Dr Shanghai East Hospital . China
Get Well Soon